Advanced Healthcare Materials Submission Guide: How to Submit to AHM (Wiley)

Advanced Healthcare Materials publishes Full Papers, Communications, Reviews, Progress Reports, Perspectives, and Comments. Contributions to most sections are written on invitation, but Full Papers and Communications are open to unsolicited submission, which is where most authors land.

Full Papers are the main unsolicited format. A Full Paper is limited to 8 journal pages, which is approximately 7,500 words and 8 display items, including figures, schemes, and tables. In practice that means up to 8 figures, schemes, and tables combined, which is a real constraint for biomaterials work, where biological validation, characterization, and mechanism figures compete for the same display-item budget. If your story needs more, the work is either a Review-length contribution or it is being framed too broadly.

Communications are shorter rapid reports of an outstanding result. A Communication that only works at Full Paper length is the wrong format, the same way a Full Paper that does not fill eight pages of validated contribution may be thin for the journal.

Reviews, Progress Reports, and Perspectives are usually invited, longer, and editorially commissioned. Submitting an unsolicited Review without prior contact with the editorial office is a common way to get a quick no.

For files, Wiley provides Word and LaTeX templates and asks authors to use them. The submission needs a data availability statement, a conflicts of interest disclosure, author contributions, ORCID iDs, supporting information, and a graphical abstract. The graphical abstract is not decoration here: for a healthcare-materials journal, it is the first place an editor checks whether the biology is visible at a glance or buried under a synthesis schematic.

Before the format and declarations are locked, an Advanced Healthcare Materials Full Paper readiness check can confirm whether your biological validation genuinely fits the eight-page Full Paper format or whether the contribution needs reframing.

Advanced Healthcare Materials assigns submissions to an editor who handles them through the ScholarOne system and the Advanced portfolio's transfer network. Community-reported SciRev data puts the first review round near one month, with about 2.3 reports per round and around 2.3 review rounds before a final decision. Treat the stages below as planning ranges, not commitments, since the SciRev sample is small.

• Day 0: Submission and record build. The ScholarOne portal ingests your template-formatted files. You confirm the cover letter, ethics statements, declarations, and graphical abstract, then submit.

• Days 1 to 5: Admin and editor screen. Editorial staff check format and length (the eight-page Full Paper cap), the ethics statement, the preprint policy, and scope.

The fastest returns happen here: out-of-scope work, over-length Full Papers, missing animal-approval statements, and preprint-deposited manuscripts rarely reach external review.

• Days 5 to 14: Editorial-board routing. An editor decides whether the work is a healthcare-materials advance or a materials-science contribution. This is where the Advanced-portfolio cascade matters: materials-led manuscripts are often declined with a transfer offer to Advanced Functional Materials, Advanced Science, or Small.

• **Days 14 to 42:

Peer review.** Single-anonymous reviewers, typically two to three reports across roughly weeks 2 to 6, focus on biological and in vitro or in vivo validation, biocompatibility rigor, and whether the material genuinely improves a healthcare outcome.

• Days 42 to 70: Decision and revision. Reject, major revision, minor revision, or accept, usually around weeks 6 to 10. A revised manuscript needs a point-by-point response letter.

Most papers that pass review go through at least one major-revision round.

• Months 2 to 3 and beyond: Final decision and production. Total handling time for accepted manuscripts runs to roughly two to three months for clean accepts, with multi-round revisions extending it. Accepted papers appear online with a 10.1002/adhm DOI before issue assignment.

In our pre-submission review work with Advanced Healthcare Materials manuscripts, four patterns generate the most consistent early returns. None of them are about the materials chemistry being wrong. They are about whether the biological validation carries the healthcare claim, which is exactly what AHM editors screen for before peer review begins.

In our review of healthcare-materials manuscripts, each of these is a named rejection pattern you can check your own draft against, and each reflects an editorial triage pattern specific to how AHM editors read submissions against the journal's biological-validation bar. The Advanced-portfolio transfer cascade raises the stakes, because a materials-led manuscript does not just get rejected, it gets routed sideways to a functional-materials venue.

Editors consistently screen for these before sending a manuscript out for review.

Advanced Healthcare Materials author guidelines and the Wiley Guide for Authors define the mechanics below; the patterns describe how manuscripts coming through pre-submission review for this journal most often fall short of them. SciRev community data on Advanced Healthcare Materials, where authors report a first review round near one month and about 2.3 reports per submission, is consistent with what we see: most attrition happens at the editorial-board screen, before reviewers ever weigh in, and these four patterns are why.

A materials-science paper wearing a healthcare label. This is the single most common stall we see at Advanced Healthcare Materials. The synthesis and characterization are strong, the abstract claims biomedical relevance, but the only biology is a sentence that the material is biocompatible. The figures are materials figures: spectra, microscopy, mechanical curves.

An AHM editor reads it and asks the load-bearing question: does the biological validation prove this material improves human health, or is the biology decoration on a materials advance? When the cell, tissue, or animal data do not carry the story, the manuscript reads as an Advanced Functional Materials paper, and the editor declines it or offers a transfer to a sister journal.

The fix is to move the biological validation from supporting to load-bearing in the abstract, the main figures, and the graphical abstract before upload.

Check whether your Advanced Healthcare Materials biological validation carries the healthcare claim →

In vitro-only claims that need in vivo evidence. The parallel failure is a cell-culture result framed as if it already proved a therapeutic, regenerative, or implant outcome. A viability or proliferation assay is used to assert that a scaffold regenerates tissue, that a nanoparticle treats a disease, or that a coating prevents infection in practice.

Reviewers in healthcare materials treat the gap between in vitro behavior and in vivo function as the whole point of the field, so an efficacy claim with no animal model, or no honest in-vitro-bounded framing, reads as overstated.

The methods and results sections are where this is decided: if the manuscript claims a healthcare effect that the experiments do not reach, the contribution is not yet ready for this journal regardless of how clean the in vitro data look.

Check if your Advanced Healthcare Materials claims match your in vivo evidence →

"Biocompatible" asserted from a single thin assay. Biocompatibility is a claim that requires an evidence package, and the recurring error is treating it as a checkbox. A single MTT or live-dead assay at one concentration and one timepoint is presented as proof of biocompatibility, with no controls, no dose-response, no degradation or host-response data, and no statistical analysis of the cell results. Reviewers read that as a token gesture rather than a result.

AHM expects a biocompatibility claim to be defended the way any other central claim is defended, with controls, replicates, and a sample size that supports the statistical analysis. A manuscript that asserts biocompatibility on one assay is one of the most predictable revision-or-reject triggers at this journal.

Check whether your Advanced Healthcare Materials biocompatibility data support the claim →

Scope drift to pure materials, plus ethics and preprint gaps. The last pattern combines two things editors catch fast. First, scope drift: the genuine contribution is a material property, a device-fabrication method, or a self-assembly mechanism, and the healthcare framing is added for fit. AHM editors are healthcare-materials specialists, and they identify quickly when the human-health advance is the setting rather than the subject.

Second, the mechanical gaps that bypass review entirely: animal experiments missing the Experimental-Section statement that names the approving authority with accreditation numbers, in vivo work that does not follow ARRIVE reporting, or a manuscript already posted on a preprint server, which AHM disallows. Either gap returns the submission before an editor evaluates the science.

This guide tells you what Advanced Healthcare Materials editors look for; a Manusights review tells you whether YOUR paper passes that screen. A Manusights review checks the biological validation, the biocompatibility evidence, the in vitro-to-in vivo logic, the format choice, and the ethics statements against the editorial bar this journal applies before peer review. Paid Manusights reviews include a 60-day money-back guarantee, and we do not train models on submitted manuscripts.

Before submitting, an Advanced Healthcare Materials validation and scope readiness check tests whether your biological validation, biocompatibility evidence, and scope framing clear the editorial bar this journal applies before peer review.

This guide was built from Advanced Healthcare Materials author guidelines, the Wiley Guide for Authors, the journal's aims and scope, the Advanced portfolio transfer network, and Manusights pre-submission review patterns from healthcare-materials manuscripts. We checked the eight-page Full Paper cap, the single-anonymous review model, the no-preprint policy, and the ARRIVE ethics requirement against Wiley's own pages, and we cross-checked review-timing ranges against SciRev community data and Clarivate JCR metrics. The failure patterns describe what we see most often when biomaterials manuscripts come through pre-submission review for this journal.

Use this page before you upload, when the official instructions cannot answer the real question: whether your biological validation, biocompatibility evidence, in vitro-to-in vivo logic, format choice, and scope framing are already defensible. Source limitation: Wiley updates format details, charges, and policies after this review date, so confirm administrative specifics against the journal's official pages before submission. To pressure-test the manuscript itself, run a manuscript readiness check.

• Acta Biomaterialia submission guide
• Biomaterials Science submission guide
• Journal of Controlled Release submission guide
• Advanced Materials submission guide
• For the broader cluster, see the biomaterials journals overview.

Before you upload, run your manuscript through an Advanced Healthcare Materials submission package check to catch the validation, biocompatibility, and scope issues editors filter for on first read. The check is free to run (/ai-review) and takes a single upload.